Immunic Therapeutics: Funding, Investors & Team (Sep 2026)
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Immunic Therapeutics has raised $545M across 4 funding rounds on record, the most recent an undisclosed round of $400M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immunic Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Immunic Therapeutics Funding Rounds
Immunic Therapeutics raised $60.0M in a Post-IPO Equity announced in Oct 2022.
1.3 years later, an undisclosed round of $80.0M was announced in Jan 2024.
1.3 years later, an undisclosed round of $5.1M was announced in Apr 2025.
10 months later, an undisclosed round of $400M was announced in Feb 2026.
Immunic Therapeutics Founders and Leadership Team
Contact details for the Immunic Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Immunic Therapeutics Funding Compared to Other Biotechnology Startups
Immunic Therapeutics' latest round of $400M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immunic Therapeutics in Biotechnology and New York
Companies Similar to Immunic Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Immunic Therapeutics Funding FAQs
What does Immunic Therapeutics do?
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
How much funding has Immunic Therapeutics raised?
Immunic Therapeutics has raised $545M across 4 rounds on record. The most recent is an undisclosed round of $400M announced in Feb 2026.
When did Immunic Therapeutics last raise funding?
Immunic Therapeutics' most recent funding round on record is an undisclosed round of $400M, announced in Feb 2026.
Who founded Immunic Therapeutics?
FundedIQ lists Andreas Muehler (Founder) at Immunic Therapeutics.
Who is the CEO of Immunic Therapeutics?
Daniel Vitt is listed as CEO at Immunic Therapeutics.
Where is Immunic Therapeutics headquartered?
Immunic Therapeutics is based in New York, United States.
How many employees does Immunic Therapeutics have?
Immunic Therapeutics is in the 51-100 employee band.
How does Immunic Therapeutics' funding compare to other Biotechnology startups?
Immunic Therapeutics' latest round of $400M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Immunic Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immunic Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.